trending Market Intelligence /marketintelligence/en/news-insights/trending/rQb3DbFOlARCnDTrCpmqZA2 content esgSubNav
In This List

UK's NICE rejects Clovis Oncology's Rubraca for certain relapsed cancers

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


UK's NICE rejects Clovis Oncology's Rubraca for certain relapsed cancers

The U.K.'s National Institute for Health and Care Excellence did not recommend Clovis Oncology Inc.'s Rubraca to treat patients with certain kinds of cancer that have returned, citing cost concerns.

NICE evaluated Rubraca, or rucaparib, as a single therapy for epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer in patients who have relapsed after taking chemotherapy.

The drug pricing watchdog stated in an Aug. 6 draft guidance that the drug costs £3,562 for a pack of 60 pills and that the average cost of treatment is £110,897.

The cancers that Rubraca is meant to treat come with a high disease burden and resistance to platinum-based chemotherapy, leading to relapse, is also high, NICE noted in the draft guidance.

But using the organization's incremental cost-effectiveness ratio, which evaluates the years of life and quality of life that a drug provides compared to its price, at £36,387 per year gained, Rubraca was above the range that NICE uses as a threshold which is £20,000 to £30,000.

Rubraca was also ineligible to be included in the U.K.'s Cancer Drugs Fund due to insufficient data.

NICE will accept comments on the draft until Aug. 27 before a second appraisal meeting Sept. 11.